Redefining functionality and treatment efficacy in multiple sclerosis

Neurology

Volumn 72, Issue 23 SUPPL. 5, 2009, Pages S1-

  Foley, John F ^a,c   Brandes, David W ^b  

^a Rocky Mountain Neurological Associates   (United States)

^b Hope MS Center   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COGNITIVE DEFECT; DEPRESSION; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FUNCTIONAL ASSESSMENT; HUMAN; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REVIEW; SCORING SYSTEM; SOCIAL DISABILITY; VISUAL DISORDER; AGE; ARTICLE; DISABILITY; HOSPITALIZATION; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

AGE FACTORS; COGNITION DISORDERS; DEPRESSION; DISABILITY EVALUATION; FATIGUE; HUMANS; MULTIPLE SCLEROSIS; PAIN; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VISION DISORDERS;

EID: 67649171647     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181a99bc2     Document Type: Article

References (62)

1. Murray TJ. Multiple Sclerosis: The History of a Disease. New York: Demos Medical Publishing; 2005.
2. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-846.
3. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome. Health Technol Assess 2004;8:1-48.
4. Hadjimichael O, Vollmer T, Oleen-Burkey M. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes 2008;6:100.
5. Rae-Grant AD, Eckert NJ, Bartz S, Reed JF. Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity. Mult Scler 1999;5:179-183.
6. Bishop M, Frain MP, Tschopp MK. Self-management, perceived control, and subjective quality of life in multiple sclerosis: an exploratory study. Rehabil Couns Bull 2008; 52:45-56.
7. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Int Med 1993;118:622-629.
8. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 2008;71:766-773.
9. Heesen C, Böhm J, Reich C, Kasper J, Goebel M, Gold SM. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 2008;14:988-991.
10. Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers CG. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009;72:705-711.
11. Bö L, Geurts JJG, Mörk SJ, van der Valk P. Grey matter pathology in multiple sclerosis. Acta Neurol Scand 2006; 113:48-50.
12. Tedeschi G, Dinacci D, Comerci M, et al. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study. Mult Scler 2009;15:204-211.
13. Geurts JJG, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol 2008;7:841-851.
14. Sanfilipo MP, Benedict RHB, Weinstock-Guttman B, Bakshi R. Gray and white matter brain atrophy and neuro-psychological impairment in multiple sclerosis. Neurology 2006;66:685-692.
15. Horakova D, Cox JL, Havrdova E, et al. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. J Neurol Neurosurg Psychiatry 2008;79:407-414.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
17. Ozakbas S, Ormeci B, Idiman E. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies. J Neurol Sci 2005;232:65-69.
18. Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, Thompson A. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult Scler 2004;10:41-46.
19. Kragt JJ, Thompson AJ, Montalban X, et al. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology 2008;70:1084-1091.
20. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G. Multiple Sclerosis Functional Composite (MSFC). Administration and scoring manual. Revised, October 2001. National Multiple Sclerosis Society. Available at: http://www. nationalmssociety.org/for-professionals/researchers/clinical-study-measures/ msfc/index.aspx. Accessed January 19, 2009.
21. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-882.
22. Hobart J, Freeman J, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000;123:1027-1040.
23. Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry 2005;76:58-63.
24. de Groot V, Beckerman H, Uitdehaag BMJ, et al. The usefulness of evaluative outcome measures in patients with multiple sclerosis. Brain 2006;129:2648-2659.
25. Sharrack B, Hughes RAC, Soudain S, Dunn G. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 1999;122:141-159.
26. Noseworthy JH. Clinical scoring methods for multiple sclerosis. Ann Neurol 1994;36:S80-S85.
27. Wynia K, Middel B, van Dijk JP, De Keyser JHA, Reijneveld SA. The impact of disabilities on quality of life in people with multiple sclerosis. Mult Scler 2008;14:972-980.
28. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler 2003;9:63-72.
29. Nortvedt MW, Riise T, Myhr K-M, Nyland HI. Quality of life as a predictor for change in disability in MS. Neurology 2000;55:51-54.
30. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008;7:1139-1151.
31. Schiffer RB. Cognitive loss. In: van den Noort S, Holland N, eds. Multiple Sclerosis in Clinical Practice. New York: Demos Medical Publishing; 1999:99-106. Adapted in National MS Society Clinical Bulletin: Cognitive loss in multiple sclerosis [online]. Available at: http://www.nationalmssociety.org/for-professionals/healthcare-professionals/ publications/clinical-bulletins/index.aspx. Accessed February 28, 2009.
32. Rao SM. Neuropsychology of multiple sclerosis. Curr Opin Neurol 1995;8:216-220.
33. Manning L. Do some neurological conditions induce brain plasticity processes? Behav Brain Res 2008;192:143-148.
34. Hoffmann S, Tittgemeyer M, Yves von Cramon D. Cognitive impairment in multiple sclerosis. Curr Opin Neurol 2007;20:275-280.
35. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002;8:448-460.
36. Benedict RHB, Duquin JA, Jurgensen S, et al. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler 2008;14:940-946.
37. Blaney BE, Lowe-Strong A. The impact of fatigue on communication in multiple sclerosis. The insider's perspective. Disabil Rehabil 2009;31:170-180.
38. Solaro C, Brichetto G, Amato MP, et al. The prevalence of pain in multiple sclerosis. A multicenter cross-sectional study. Neurology 2004;63:919-921.
39. Grasso MG, Clemenzi A, Tonini A, et al. Pain in multiple sclerosis: a clinical and instrumental approach. Mult Scler 2008;14:506-513.
40. Frohman EM. Vision. In: van den Noort S, Holland N, eds. Multiple Sclerosis in Clinical Practice. New York: Demos Medical Publishing; 1999:89-98. Adapted in National MS Society Clinical Bulletin: Diagnosis and management of vision problems in MS [online]. Available at: http://www. nationalmssociety.org/for-professionals/healthcare-professionals/publications/ clinicalbulletins/index.aspx. Accessed February 28, 2009.
41. Frohman EM, Fujimoto JG, Frohman TC, Calabresi PA, Cutter G, Balcer LJ. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol 2008;4:664-675.
42. Ma S-L, Shea JA, Galetta SL, et al. Self-reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire. Am J Opthalmol 2002;133:686-692.
43. Balcer LJ, Galetta SL, Calabresi PA, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007;68:1299-1304.
44. Siegert RJ, Abernathy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 2005;76:469-475.
45. Kurt A, Nijboer F, Matuz T, Kübler A. Depression and anxiety in individuals with amyotrophic lateral sclerosis. Epidemiology and management. CNS Drugs 2007;21:279-291.
46. Koch M, Uyttenboogaart M, van Harten A, Heerings M, De Keyser J. Fatigue, depression and progression in multiple sclerosis. Mult Scler 2008;14:815-822.
47. Arnett PA, Barwick FH, Beeney JE. Depression in multiple sclerosis: review and theoretical proposal. J Int Neuropsychol Soc 2008;14:691-724.
48. Brown RF, Valpiani EM, Tennant CC, et al. Longitudinal assessment of anxiety, depression, and fatigue in people with multiple sclerosis. Psychol Psychother 2009;82:41-56.
49. Beal C, Stuifbergen AK, Sands DV, Brown A. Depression in multiple sclerosis: a longitudinal analysis. Arch Psychiatr Nurs 2007;21:181-191.
50. Mitchell AJ, Benito-León J, Gonzalez J-MM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 2005;4:556-566.
51. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007;62:335-346.
52. Hobart J, Freeman J, Lamping D, Fitzpatrick R, Thompson A. The SF-36 in multiple sclerosis: why basic assumptions must be tested. J Neurol Neurosurg Psychiatry 2001; 71:363-370.
53. Isaksson A-K, Ahlström G, Gunnarsson L.-G. Quality of life and impairment in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:64-69.
54. Kos D, Nagels G, D'Hooghe MB, Duportail M, Kerckhofs E. A rapid screening tool for fatigue impact in multiple sclerosis. BMC Neurol 2006;6:27.
55. Scherer P, Bauer H, Baum K. Alternate finger tapping test in patients with migraine. Acta Neurol Scand 1997;96: 392-396.
56. Reddy H, Narayanan S, Woolrich M, et al. Functional brain reorganization for hand movement in patients with multiple sclerosis: defining distinct effects of injury and disability. Brain 2002;125:2646-2657.
57. Moran PJ, Mohr DC. The Validity of Beck Depression Inventory and Hamilton Rating Scale for Depression items in the assessment of depression among patients with multiple sclerosis. J Behav Med 2005;28:35-41.
58. Marrie RA, Goldman M. Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler 2007;13:1176-1182.
59. Frohman EM, Stüve O, Havrdova E, et al. Therapeutic considerations for disease progression in multiple sclerosis. Evidence, experience, and future expectations. Arch Neurol 2005;62:1519-1530.
60. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.
61. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
62. Lawton MP, Brosy EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.